Results 121 to 130 of about 2,662,283 (378)

Effects of synthesis conditions on particle size and pore size of spherical mesoporous silica

open access: yesMaterials Research Express
The particle size and pore size of spherical mesoporous silica materials play significant roles in their application. However, relatively limited systematic research has been conducted on how preparation conditions influence these properties.
Shu Xu   +3 more
doaj   +1 more source

Lie Symmetries of the Wave Equation on the Sphere Using Geometry

open access: yesDynamics
A semilinear quadratic equation of the form Aij(x)uij=Bi(x,u)ui+F(x,u) defines a metric Aij; therefore, it is possible to relate the Lie point symmetries of the equation with the symmetries of this metric. The Lie symmetry conditions break into two sets:
Michael Tsamparlis   +1 more
doaj   +1 more source

Unlocking the potential of tumor‐derived DNA in urine for cancer detection: methodological challenges and opportunities

open access: yesMolecular Oncology, EarlyView.
Urine is a rich source of biomarkers for cancer detection. Tumor‐derived material is released into the bloodstream and transported to the urine. Urine can easily be collected from individuals, allowing non‐invasive cancer detection. This review discusses the rationale behind urine‐based cancer detection and its potential for cancer diagnostics ...
Birgit M. M. Wever   +1 more
wiley   +1 more source

Isometries of Spheres [PDF]

open access: yesProceedings of the American Mathematical Society, 1995
In a Euclidean space of dimension two or more, any mapping that preserves unit distance is an isometry; this is the theorem of Beckmann and Quarles. We prove a similar theorem for spheres, assuming that a given distance less than a quarter great circle is preserved.
openaire   +2 more sources

Surfaceome: a new era in the discovery of immune evasion mechanisms of circulating tumor cells

open access: yesMolecular Oncology, EarlyView.
In the era of immunotherapies, many patients either do not respond or eventually develop resistance. We propose to pave the way for proteomic analysis of surface‐expressed proteins called surfaceome, of circulating tumor cells. This approach seeks to identify immune evasion mechanisms and discover potential therapeutic targets. Circulating tumor cells (
Doryan Masmoudi   +3 more
wiley   +1 more source

Clinical applications of next‐generation sequencing‐based ctDNA analyses in breast cancer: defining treatment targets and dynamic changes during disease progression

open access: yesMolecular Oncology, EarlyView.
Circulating tumor DNA (ctDNA) offers a possibility for different applications in early and late stage breast cancer management. In early breast cancer tumor informed approaches are increasingly used for detecting molecular residual disease (MRD) and early recurrence. In advanced stage, ctDNA provides a possibility for monitoring disease progression and
Eva Valentina Klocker   +14 more
wiley   +1 more source

Circulating tumor cells in metastatic breast cancer patients treated with immune checkpoint inhibitors – a biomarker analysis of the ALICE and ICON trials

open access: yesMolecular Oncology, EarlyView.
In this explorative biomarker analysis, we assessed serial sampling of circulating tumor cells (CTCs) with CellSearch in two randomized trials testing immune checkpoint inhibitors (ICIs) in metastatic breast cancer. Our data demonstrate a prognostic potential of CTCs, most apparent 4 weeks into ICI therapy.
Nikolai Kragøe Andresen   +13 more
wiley   +1 more source

Circulating tumor cells: advancing personalized therapy in small cell lung cancer patients

open access: yesMolecular Oncology, EarlyView.
Small cell lung cancer (SCLC) is an aggressive form of lung cancer that spreads rapidly to secondary sites such as the brain and liver. Cancer cells circulating in the blood, “circulating tumor cells” (CTCs), have demonstrated prognostic value in SCLC, and evaluating biomarkers on CTCs could guide treatment decisions such as for PARP inhibitors ...
Prajwol Shrestha   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy